Where Fate Therapeutics Stands With Analysts

6 analysts have shared their evaluations of Fate Therapeutics FATE during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Fate Therapeutics, revealing an average target of $7.33, a high estimate of $10.00, and a low estimate of $6.00. Marking an increase of 83.25%, the current average surpasses the previous average price target of $4.00.

Diving into Analyst Ratings: An In-Depth Exploration

The perception of Fate Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fate Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fate Therapeutics compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Fate Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fate Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Fate Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Unraveling the Financial Story of Fate Therapeutics

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Fate Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -96.22%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Fate Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2632.58%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Fate Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -11.44%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Fate Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -8.4%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Fate Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.28, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.